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Abstract
Nuclear factor-κB (NF-κB) is one of the main regulators of inflammatory
and immune responses. It is a family of transcription factors composed of five
members: RelA, RelB, cRel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). Homoand hetero-dimers of family members are inhibited by inhibitor of κB (IκB) family
members and activated by IκB kinase (IKK) family members. The IKK family is
comprised of IKKγ, IKKα, and IKKβ. The focus of my dissertation delves into the
role of NF-κB activation by IKKβ in both an immunotherapy setting and its role in
T cell mediated anti-tumor immune responses.
A central focus of immunotherapy is to develop vaccine adjuvants that are
capable of enhancing a protective adaptive immune response. Microbial
adjuvants in vaccines activate key transcription factors, including NF-κB and
interferon response factors (IRF). The individual role of these transcription factors
in successful vaccines is not clear. We used constitutively active IKKβ (CA-IKKβ)
expressed in an adenoviral vector (AdIKK) to determine the role of classical NFκB activation in a vaccine-induced immune response. In an in vivo model, AdIKK
induced rapid and sustained NF-κB-driven inflammation in the lungs compared to
the control virus. AdIKK infection had no impact on the magnitude of T cell
activation as measured by IFN-γ production; however pulmonary inflammation
v

resulted in increased cellularity of draining lymph nodes (LN) at early timepoints
resulting in increased early antibody and T cell responses. Taken together, these
findings show that IKKβ-induced NF-κB activation of an inflammatory response
affects the kinetics, but not the magnitude of the adaptive immune response.
NF-κB is activated in many tumor types and contributes to the progression
of cancer by suppressing apoptosis, and enhancing proliferation, angiogenesis
and metastasis. NF-κB is also activated in other cells within the tumor
microenvironment and promotes inflammation initiated by neutrophils and
macrophages. In addition to inflammatory cells, T cells can be found within the
tumor microenvironment and are associated with improved patient survival.
Using CA-IKKβ, we sought to determine if NF-κB activation in tumor cells could
promote T cell mediated tumor immunity. In both primary tumors and a
metastatic tumor model, we found that NF-κB expression in tumors rendered
immunogenic through expression of Kb-OVA led to tumor rejection or growth
suppression. Tumor regression was mediated by increased CD8 T cell
recruitment by chemokines. Microarray results showed increases in T cell
chemokines, including CCL2 and CCL5. Knock-down of CCL2 by Lentiviral
shRNA in LLC-OVA-IKK cells resulted in abrogation of tumor regression. These
results suggest that NF-κB is capable of promoting immune surveillance in
tumors through increased recruitment of T cells.
Overall, my dissertation highlights beneficial roles of IKKβ-induced
activation of NF-κB in two separate systems: vaccine induced immune responses
and tumor immune surveillance.
vi

Chapter 1. An introduction to innate immunity and NF-κ
κB

1.1 Innate immunity
The immune system is comprised of a series of layered defenses. Each
layer becomes increasingly more specific, starting from a non-specific general
barrier such as the skin, down to receptors specific for just a few peptides in T
cells. These various layers can be broken down into two groups: the innate
immune system, and the adaptive immune system. Once microorganisms breech
our physical barriers, the innate immune system becomes the first line of defense
and is capable of initiating a rapid response. The innate immune system is
responsible for activating the adaptive immune response, which is charged with
generation of immunological memory. Cross-talk between these two systems is
vital for a successful immune response.
1.1.1. The innate immune response
Once microorganisms break past our primary immune barriers, such as
the skin and mucosal epithelium, the cells of the innate immune system become
responsible for taking up the fight against the intruders. The cells that play a role
in this fight include neutrophils, basophils, and eosinophils, collectively termed
polymorphonuclear leukocytes (PMNs), macrophages, dendritic cells (DCs), and
natural killer (NK) cells (1).

1

The cells in the innate immune system are capable of distinguishing self
from non-self through pattern recognition receptors (PRRs) that recognize
pathogen-associated molecular patterns (PAMPs) (2-4). PRRs function to
activate complement, promote phagocytosis, and trigger the expression of
inflammatory cytokines, chemokines, type I IFNs, and co-stimulatory molecules
(1).
The best-studied PRR family is the Toll-like receptor (TLR) family. TLRs
dictate specificity through their location and recognition of specific PAMPs. For
instance, TLR4 recognizes LPS and is located on the cell surface, whereas TLR9
is located on the endosomal membrane and recognizes unmethylated CpG (5).
All TLRs contain a conserved Toll-IL-1R (TIR) domain at the carboxyl
terminus located in the cytoplasm. The TIR domain is responsible for recruiting
adaptors to the TLR that can initiate cascades to activate transcription factors.
Virtually all TLRs activate key transcription factors, including NF-κB and
interferon (IFN) response factors (IRF); which play an integral role in promoting
the adaptive immune response (6).
While TLR family members recognize PAMPs on the cell surface or
endosomal membrane, other PRRs recognize PAMPs found within the cytoplasm
(4, 7, 8). Various cytoplasmic PRRs exist and they are generally organized into
two subfamilies: nucleotide binding oligomerization domain-leucine rich repeat
(NOD-LRR) proteins and caspase activation and recruitment domain (CARD)helicase proteins (4).
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Members of the NOD-LRR family of proteins are responsible for
recognizing bacterial components within the cytoplasm. Two of the best-studied
NOD-LRR proteins, NOD1 and NOD2, are also capable of activating NF-κB for
the induction of pro-inflammatory cytokines (8, 9). Proteins in this family combine
to form macromolecular complexes called inflammasomes that recognize
danger-associated molecular patterns and initiate an inflammatory response.
The CARD-helicase proteins are responsible for recognizing dsRNA
produced by viruses in the cytoplasm (10). Two members of this family include
retinoic acid-inducible protein I (RIG-I) and melanoma differentiation-associated
gene 5 (MDA5). These closely related proteins are activated by dsRNA produced
by viruses and association with the adaptor protein interferon β promoter
stimulator 1 (IPS-1) results in downstream activation of the NF-κB and IRF
transcription factor families (4, 11, 12).
During an infection, ligation of PRRs on resident leukocytes or viral
infected

cells

results

in

the

production

of

inflammatory

chemokines.

Chemokines function to recruit additional leukocytes, such as neutrophils and
macrophages, to the area to initiate an inflammatory response and phagocytose
necrotic cell debris or microbes (13). Chemokines are also responsible for
bringing T cells into contact with dendritic cells to either initiate an adaptive
immune response, in the case of infection, or to initiate tolerance, in the case of
self antigens (14). Our lab, and others, have shown that the transcription factor
NF-kB is responsible for the activation of many chemokines, such as CXCL1,
CXCL2, IL-8, CXCL10, CCL2, and CCL5 (15-17).
3

1.1.2. Dendritic cells: Linking innate and adaptive immunity
As mentioned above, the innate immune system consists of several
different cells: neutrophils, basophils, and eosinophils, macrophages, dendritic
cells (DCs), and natural killer (NK) cells (1).
Natural killer cells are unique among innate immune cells because they
are capable of directly lysing cells by releasing perforin and granzyme once they
are activated by type I IFN and interleukin (IL-12) (18). Neutrophils and
macrophages function as phagocytes and are capable of engulfing and killing
microbial pathogens. A second function of macrophages includes recognition of
PAMPs (discussed above) and secretion of cytokines and chemokines to initiate
inflammation. Like macrophages, DCs also recognize PAMPs; however, unlike
macrophages, DCs are the only professional antigen presenting cell (APC)
capable of activating naïve T lymphocytes (19-22). This unique ability makes
DCs an important bridge between the innate immune response and the adaptive
immune response.
Immature DCs (iDCs) act as watchdogs of the innate immune system.
They constantly patrol peripheral tissues sampling antigens. In the immature
state, they express low levels of major histocompatibility complex (MHC) and costimulatory molecules, but are highly phagocytic.
In the absence of danger signals, iDCs are responsible for inducing
peripheral tolerance to self antigens (23). When danger signals are initiated
through bacterial or viral products, iDCs process pathogen antigens and express
them in complex with MHC molecules on the cell surface. These activated iDCs
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then undergo maturation (19-21). Mature DCs migrate to the lymph nodes,
increase the expression of co-stimulatory molecules (CD40, CD80, CD86),
secrete inflammatory cytokines and up-regulate MHC-peptide complexes on their
surface. Once DCs arrive at the lymph nodes, T cells can be fully activated.
Activation of T cells by DCs is a three step process. First, T cell receptors (TCR)
must recognize the MHC:peptide complex presented. Second, co-stimulatory
molecules on the APC (CD80 and CD86) must bind CD28 expressed on the T
cell. Finally, the APC must secrete cytokines to direct the maturation of the T
cells (19, 20, 22, 23). Previous work in our lab has shown that the transcription
factor NF-κB plays an integral role in the activation of T cells by DCs. NF-κB is
required for expression of costimulatory molecules as well as pro-inflammatory
cytokines produced by DCs (24).

1.2. An introduction to NF-κ
κB
As a main regulator of many immunological processes, the transcription
factor NF-κB has garnered the attention of many researchers in the past few
decades. Since its discovery in 1986, over 40,000 articles have been published
on the family. As the name suggests, it was first discovered as a protein in the
nucleus of B cells that binds kappa light chain enhancer sequences (25). Since
its initial discovery, research has shown that NF-κB is ubiquitously expressed
and is capable of activating a wide range of genes with varying functions, from
activation of the immune response to inhibition of apoptosis (26, 27) Due to its
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broad and varied functions, NF-κB has been found to play a role in a myriad of
human diseases, from autoimmunity to cancer (28-31).
1.2.1. The NF-κ
κB family
The NF-κB family is comprised of 5 transcription factors: RelA (p65), RelB,
cRel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52) (Figure 1.1). All five members
contain a highly conserved rel homology region (RHR) as well as a DNA binding
domain (DBD) that allows DNA binding as well as dimerization with other family
members and binding of the inhibitors of κB (IκB) (32). The active transcription
factor exists as a dimer that is sequestered in the cytoplasm by inhibitors.
Three members of the family, RelA, RelB, and cRel, contain a
transactivation domain on their carboxyl terminus and are capable of activating
transcription when released from their inhibitors. Although these three factors are
highly homologous, they have functional specificity, highlighted in previous
genetic knockout studies (24, 33-36).
NF-κB1/p50 and NF-κB2/p52 have a transrepression domain instead of a
transactivation domain; therefore they cannot activate transcription unless
partnered with one of the other three family members. These two proteins must
be processed through proteasomal degradation of their precursors (p105 and
p100) before they can become activated. Homodimers of p50 or p52 typically act
as repressors of transcription (37).
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RHD

TD

RelA
cRel
RelB
p100/p52
p105/p50
ARM
IκBα
IκBβ
IκBγ
IκBε
Bcl-3
IκBζ
IκBNS
KD

LZ

HLH

IKKα/β
IKKγ
CC1

CC2

Zn

Figure 1.1. The mammalian NF-κB and IκB families and IKK subunits.
Slashes show cleave site on p100 and p105 to generate p52 and p50. RHD:
rel-homology domain. TD: transactivation domain. ARM: ankyrin repeat
motif. KD: kinase domain. LZ: leucine zipper. HLH: helix-loop-helix. CC:
coiled-coil. Zn: zinc finger.
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1.2.2. Two pathways of activation
Activation of NF-κB can occur through two general pathways: the classical
(Figure 1.2), and the alternative pathway (Figure 1.3). In a resting cell, NF-κB is
sequestered in the cytoplasm by the inhibitors of kB (IκB). These proteins, along
with NF-κB1 and NF-κB2, contain ankyrin repeat motifs (ARMs) that bind the
RHR of NF-κB proteins. This binding masks the nuclear localization sequence,
which sequesters NF-κB in the cytoplasm (38-40). Upon stimulation, NF-κB is
released from IκB through activation of the IκB kinase (IKK) complex. Activation
of the classical or the alternative pathway of NF-κB is dependent on the
presence or absence of IKKγ (27, 41-43).
1.2.2a. The classical pathway
The classical pathway (Figure 1.2) is activated by stimuli such as ligation
of TLRs, TNFR, or IL-1R and typically results in the activation of p50, RelA,
and/or cRel and induction of inflammatory cytokines and chemokines such as IL1β, TNFα, IL-6, IL-8, and KC (17). The IKK complex responsible for activation of
the classical pathway is composed of the regulatory subunit IKKγ and two
catalytic subunits, IKKα and IKKβ (44, 45) (Figure 1.1).
Upon stimulation, IKKβ is phosphorylated on serines 177 and 181
downstream of MAPK pathways and activates IKKβ allowing phosphorylation of
IκB (46, 47). Phosphorylation of IκBα on serines 32 and 36 mark it for
ubiquitination by the E3 ligase, β-TrCP/SCF and subsequent degradation by the
26S proteasome. Once IκB is released, NF-κB is free to translocate to the
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TNFR, TLR, IL-1R

Cell membrane

IKKγ
IKKβ

IKKα

IκBα
β-TrCP
IκBα

RelA
p50

IκBα

Phos
Ub

RelA
p50
RelA
p50

Nuclear
membrane

proteasomal
degradation
RelA
p50
transcription

Figure 1.2. The core classical NF-κB pathway. Extracellular stimuli
activate various pathways leading to the phosphorylation of IKKβ in the
classical IKK complex. IKKβ phosphorylates IκB resulting in its
ubiquitination by β-TrCP and degradation by the 26S proteasome.
Freed NF-κB dimers, shown here as p50/RelA, translocate to the
nucleus, bind κB sites and initiate gene transcription. Phos: phosphate,
Ub: ubiquitin.
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nucleus (26, 27, 37, 48). My research focused on the use of constitutively active
IKKβ for activation of NF-κB in the immune response. IKKβ will be discussed
further in section 2.3.
1.2.2b. The alternative pathway
The alternative pathway (Figure 1.3) is most commonly activated in
response to members of the TNF superfamily, such as lymphotoxin β (49-51),
CD40 (52), and B cell activating factor (BAFF) (53). Its activation is dependent on
IKKα phosphorylation of NF-κB2/p100. This results in partial degradation of p100
to the active form, p52 and allows the p52/RelB complex to translocate to the
nucleus (54, 55). The alternative pathway plays a part in adaptive immunity
through its role in lymphoid organogenesis (34, 56, 57).
1.2.3. IKKβ
β
As discussed in section 2.2.1, the classical pathway of NF-κB activation
hinges on phosphorylation of IKKβ. IKKβ was first discovered in 1997 (44) when
it was teased out of the IKK signalosome identified in the previous year (58). The
crystal structure of IKKβ was characterized in 2011 and differs somewhat from
the accepted predicted structure (46, 59). Both the predicted and the crystalized
structure of IKKβ contain a kinase domain on the amino terminus, and a NEMO
(IKKγ) binding domain (NBD) on the carboxyl terminus; however, the crystal
structure identif ies a ubiquitin-like d omain (ULD) and an α-helical
scaffold/dimerization domain (SDD), which takes the place of the predicted
leucine zipper (LZ) and helix-loop-helix (HLH) motifs. IKKβ interacts with IκBα
through the ULD and SDD (59).
10

CD40, LTβ, BAFF
Resting

Stimulated
Phos
Ub

Cell membrane
c-IAP1/2 TRAF3

c-IAP1/2 TRAF3
TRAF2

TRAF2
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NIK

NIK
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TRAF3

IKKα

NIK

IKKα

p100
RelB
p52

proteasomal
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Nuclear
membrane

RelB

p52
RelB

transcription

Figure 1.3. The alternative NF-κB pathway. In resting cells, NIK is
ubiquitinated by c-IAP1/2, keeping NIK levels low. Upon stimulation, cIAP1/2 ubiquitinates TRAF3, releasing NIK and allowing its accumulation
and activation. Active NIK phosphorylates IKKα and IKKα can then
phosphorylate p100, resulting in its processing to p52. Free p52/RelB can
the translocate to the nucleus to induce target gene transcription. Phos:
phosphate. Ub: ubiquitin.
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Despite the discrepancy between the predicted and crystal structures,
activation of IKKβ still requires phosphorylation of serines 177 and 181 within the
kinase domain. How the phosphorylation of IKKβ occurs is still under discussion.
The crystal structure of IKKβ, combined with knowledge garnered from previous
crystal structures of IKKγ suggest that higher order oligomerization is responsible
for trans-autophosphorylation (59). Mutation of serines 177 and 181 to glutamic
acid produces a constitutively active form of IKKβ (CA-IKKβ). CA-IKKβ is
sufficient for activation of classical NF-κB subunits (46); as such, it is a powerful
tool for studying the activation of NF-κB in a variety of settings. Here, we have
used CA-IKKβ to examine the role of IKKβ-induced NF-κB activation in a vaccine
setting as well as in a tumor-induced immune response.

1.3. The role of NF-κ
κB in vaccine-induced immunity
One of the many beneficial roles of NF-κB includes the induction of
cytokines necessary to activate the adaptive immune response. During an
infection, microbial adjuvants are recognized by dendritic cells (DCs) through
pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) (4, 60,
61). TLR ligation results in the activation of key transcription factors, including
NF-κB and interferon response factors (IRFs) (62).
It is widely believed that induction of a strong innate inflammatory
response potentiates an adaptive immune response. In the case of a successful
vaccine, microbial adjuvants also activate NF-κB and IRFs (63). This combined
activation is responsible for the induction of the active form of IL-12 that can push
12

the immune response towards Th1-biased activation necessary for cell-mediated
immunity (64); however, the individual roles of these transcription factors remains
unclear.
Despite successes in limiting infectious diseases, vaccines for noninfectious diseases have fallen short. In the case of cancers, prophylatic or very
early treatments have proven successful; yet this does not help the majority of
cancer patients who typically present with well-established tumors. As such, a
major goal of current immunotherapy is the development of strategies to treat
established tumors (65-67). Before this can be done, a better understanding of
what makes a successful vaccine is necessary.
One of the most common viral vectors used for immunotherapy are nonreplicating adenoviruses (68-71). These viruses are in use in the clinic as standalone agents as well as viral vectors for DC vaccines (66, 71). These vectors are
one of the most efficient vehicles for delivering genetic material to DCs with
limited cellular toxicity. In DCs, adenoviral vectors induce maturation via an NFκB-dependent pathway (72) and type I IFN signaling (73).
In chapter 2, we use an adenoviral vector to define the role of IKKβinduced activation of NF-κB on the immune response to a virally encoded
antigen. This approach gives us a clinically relevant model to examine and define
the role of other activators of NF-κB and other transcription factors in a similar
setting.
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1.4. NF-κ
κB in cancer
Very generally, cancer can be defined as uncontrolled cell growth. More
specifically, Hanahan and Weinberg classified six hallmarks of cancer within the
cell that dictate malignant growth. These alterations are: self-sufficiency in growth
signals, insensitivity to anti-growth signals, evasion of programmed cell death
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue
invasion and metastasis (74). Inflammation has been suggested as a seventh
hallmark of cancer (75-77).
Upregulation of NF-κB is present in many cancers, including lung cancer
(78), melanoma (79), multiple myeloma (80), breast cancer (81), colorectal
cancer (82), and lymphoma (83). NF-κB has been shown to play a role in at least
some of the hallmarks of cancer, including self-sufficiency in growth signals,
evasion of apoptosis, sustained angiogenesis, and invasion and metastasis (78,
79, 83-87). One of the most obvious links between NF-κB and cancer is the
inhibition of apoptosis (88). In a normal cell, NF-κB regulates apoptosis by
targeting genes such as Bcl-xL, inhibitors of apoptosis (IAPs), and c-FLIP.
A link between inflammation and cancer has been suspected since the
19th century when Virchow noted that inflammatory cells were present in tumor
biopsies from patients (89). Prolonged inflammation, as well as exposure to
carcinogens and inflammatory agents increase the risk of cancer (90-92). This
link between inflammation and cancer has led many researchers to study the role
of NF-κB in the tumor environment (31, 93-95).
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NF-κB plays a role in the recruitment of tumor-promoting inflammatory
cells, such as neutrophils and macrophages; however, NF-κB can also activate T
cells and promote T cell-mediated tumor suppression (30). How can these two
seemingly opposing functions of NF-κB be reconciled? Are they present in the
same tumor, and what determines whether NF-κB activation in the tumor is good
(immune promoting) or bad (tumor promoting)? Many questions about the
function of NF-κB in immunogenic tumors still remain to be answered. In chapter
3, we attempt to shed a little light on this subject.
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Chapter 2. IKKβ
β-induced inflammation impacts the kinetics but not the
magnitude of the immune response to a viral vector

2.1. Abstract
Microbial adjuvants in vaccines activate key transcription factors, including
NF-κB and interferon response factors (IRFs). However, the individual role of
these transcription factor pathways in promoting adaptive immunity by adjuvants
is not clear. It is widely believed that induction of a strong inflammatory response
potentiates an adaptive immune response. In this study, we sought to determine
whether activation of the pro-inflammatory inhibitor of κB kinase IKK) canonical
NF-κB pathway promoted vaccine-induced immune responses. An adenovirus
expressing constitutively-activated IKKβ (AdIKK) induced robust DC maturation
and high expression of key cytokines compared to a control virus. In vivo, AdIKK
triggered rapid inflammation after pulmonary infection, increased leukocyte entry
into draining LNs, and enhanced early antibody and T-cell responses. Notably,
AdIKK did not influence the overall magnitude of the adaptive immune response.
These results indicate that induction of inflammation by IKKβ/NF-κB in this
setting impacts the kinetics but not the magnitude of adaptive immune
responses. These findings therefore help define the individual role of a key
pathway induced by vaccine adjuvants in promoting adaptive immunity.
16

2.2. Introduction
Despite the tremendous success of vaccines in limiting the spread of
infectious diseases, the underlying mechanisms through which successful
vaccines work are only beginning to be understood. A central focus of current
research is to define innate immunity mediators that can function as adjuvants to
enhance protective adaptive immunity (96). The discovery and utilization of novel
adjuvants can be instrumental in enhancing vaccine efficacy against infectious
agents and cancer (96, 97). Mammalian PRRs, including TLRs, induce
intracellular signaling in response to a plethora of microbial agents resulting in
induction of robust innate and adaptive immune responses (4, 60, 61). Specific
TLR ligands therefore have efficacy as vaccine adjuvants (96). Two main classes
of transcription factors are activated by virtually all TLR ligands: NF-κB and IRF
(4, 98). However, the individual role of these transcription factor pathways in
promoting immune response by vaccines is not clear. NF-κB plays a key role in
regulating expression of genes involved in inflammation, innate and adaptive
immunity (11, 24, 43, 99-104). NF-κB activation is mediated by IKKβ

(the

canonical pathway) and IKKα (the non-canonical pathway), both of which are
regulated by NIK (17, 41, 105, 106). The goal of this study was to specifically
define the role of the IKKβ canonical pathway in promoting vaccine-induced
immune responses. We tested this in the context of an adenovirus vector, which
are in clinical use as stand-alone vaccines (69, 70) and as antigen-expressing
vectors for DCs (107).
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2.3. Methods
2.3.1. Mice
Six to 8-week-old C57BL/6 mice were purchased from the National
Cancer Institute (Frederick, MD). Six to 8-week-old Balb/C mice were purchased
from Harlan Laboratories (Indianapolis, IN). OT-1 and OT-II mice were
purchased from Jackson Laboratories (Bar Harbor, ME) and were bred at our
animal facility. Mice were housed at the Comparative Medicine Facility at the
Moffitt Cancer Center and Research Institute. p50-/-cRel-/- and RelA-/- have
been described previously and were bred in-house (108). IFNAR-/- mice were
kindly provided by Dr. Esteban Celis (Moffitt Cancer Center). NF-κB-luciferase
mice were kindly provided by Dr. Noreen Luetteke (Moffitt Cancer Center). All
colonies were maintained under specific pathogen free conditions. All
experiments were performed following the guidelines of the Moffitt Cancer Center
and the University of South Florida Institutional Animal Care and Use Committee.
2.3.2. Cell culture
293T cells were cultured in DMEM/10% FBS supplemented with 2 mM Lglutamine and antibiotics. AD-293 cells were purchased from Stratagene (Santa
Clara, CA) and were cultured in 293T medium supplemented with 1 mM sodium
pyruvate.
Bone marrow-derived dendritic cells (BMDC) were made from BM
suspensions flushed from femurs and tibias of mice. Briefly, cells were cultured in
24-well plates in RPMI-1640 supplemented with 5% fetal bovine serum,
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antibiotics, L-glutamine, and 2-ME in the presence of supernatant (3% vol/vol)
from J558L cells transduced with murine GM-CSF at a density of 1x106 cells/ml.
DC clusters were harvested after 6 days of cultures and transferred to new 24well plates at a density of 1-2x106 cells/ml. DC generated were >95% CD11c+.
For antigen stimulation, DC were pulsed with OVA peptide (SIINFEKL) overnight
prior to infection. For injection, DC were harvested 48h after infection and
injected subcutaneously or intravenously.
Human peripheral blood mononuclear cells (PBMCs) were isolated
normal donor buffy coats (Florida Blood Services) as described (109) with minor
changes. Cells were cultured at 4-5.5x106 cells/ml in complete medium
supplemented with 5 ng/ml of GM-CSF and IL-4. Additional growth factors were
added on day 3 and monocyte-derived dendritic cells (MoDCs) were harvested
on day 5.
2.3.3. Adenovirus production and infection
Replication deficient AdGFP and AdIKK were purchased from Vector
Biolabs. AdIKK was produced by cloning IKKβEE into the DUAL-GFP-CCM
shuttle vector. Adenovirus stocks were amplified by serial culture in AD-293 cells.
Virus was harvested from AD-293 cells using 4 freeze-thaw cycles in a dry
ice/ethanol bath and a 37ºC water bath with vortexing between each cycle. Virus
was purified and concentrated via CsCl density centrifugation after 3-4 rounds of
amplification. Virus titers were determined using QuickTiter™ Adenovirus Titer
Immunoassay Kit (Cell Biolabs, San Diego, CA) according to manufacturer’s
instructions. All purified virus stocks were tested for the presence of endotoxin
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using the Limulus Amebocyte Lysate Assay with a sensitivity of 0.03 EU/ml
(Associates of Cape Cod, East Falmouth, MA) using 10-fold serial dilutions of the
virus. All stocks were negative for endotoxin at the 1:100 dilution.
HEK-293T cells were infected with adenovirus for 48 hours. BMDCs were
infected with AdIKK or AdGFP on day 7 of culture for 48 hours. MoDCs were
infected on day 5 of culture at an MOI of 500 in a minimal volume for 3 hours with
occasional shaking, then cells were plated and cultured for 48 hours prior to
analysis. Mice were given adenovirus subcutaneously in four sites for each
mouse: each flank, tail base and scruff, or intratracheally. Intratracheal
administration was performed under anesthesia with 3-5% Isoflurane. Mice were
secured in a supine position on an incline of 30-45º, and the larynx was
visualized with an otoscope. Upon visualization, 50 µl of virus was administered
into the trachea using a catheter. Mice were euthanized by CO2 inhalation.
2.3.4. Flow cytometric analysis
Uninfected (PBS), AdGFP, and AdIKK infected cells were collected and
incubated in PBS/0.5% bovine serum albumin with anti-CD16/CD32 for five
minutes at room temperature (RT) to inhibit Fc binding of antibodies. Then cells
were stained with antibodies to CD11c-, B7.1-, B7.2, MHC I (H2K)-, MHC II (IA)or ICAM 1-PE for 20 minutes on ice. All mouse and human antibodies were
purchased from BD Biosciences-Pharmingen (San Diego, CA). Human MoDC
were gated on Lin negative, HLA-DR positive populations. Flow cytometric
analysis was performed on an LSR II cytometer (BD Biosciences, San Jose, CA).
Aggregates and dead cells were excluded from analysis (110). Data were
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acquired using CellQuest software (BD Biosciences, San Jose, CA) and
analyzed using FlowJo software (Tree Star, Ashland, OR).
2.3.5. T cell proliferation
CD8 T cells were purified from OT-I transgenic mice by negative selection
using antibodies to CD4, CD11b, CD11c, CD19, CD45R, CD49b, CD105, AntiMHC-class II, and Ter-119 according to the manufacturer’s instructions (Miltenyi
Biotec, Auburn, CA). DC were pulsed with OVA (257-264) peptide (SIINFEKL)
overnight and then infected with AdGFP or AdIKK for 48 hours. CD4 T cells were
purified from OT-II transgenic mice by negative selection using antibodies to
CD8a, CD11b, CD11c, CD19, CD45R, CD49b, CD105, Anti-MHC-class II, and
Ter-119 according to the manufacturer’s instructions. DC were pulsed with OVA
(323-339) peptide overnight and then infected with AdGFP or AdIKK for 48
hours. DC were then co-cultured with OT-I CD8 T cells or OT-II CD4 T cells and
proliferation was measured by

3

H-thymidine incorporation as previously

described (111)
2.3.6. Tissue histology and luciferase imaging
For histology, lungs were removed, inflated with 10% formalin, sutured
and fixed in formalin for at least 18 hours. Sutures were removed and lungs were
embedded in paraffin blocks. Lung sections were examined after hematoxylin
and eosin staining. Mediastinal lymph nodes were embedded in Tissue Tek OCT
compound (Sakura Fintek, Torrance, CA), and stained with hematoxylin and
eosin. Lymph nodes were imaged on an Aperio ScanScope XT Automated Slide
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Scanner (Vista, CA). NF-κB activation in the lungs of NF-κB luciferase mice was
determined as previously described (112) with changes. Ten minutes after Dluciferin was injected, mice were euthanized by CO2 inhalation and lungs were
removed for imaging. Imaging was completed within 15 minutes after tissue
harvesting on a Caliper Ivis 200 (Caliper Life Sciences, Hopkinton, MA).
2.3.7. Western blotting and electrophoretic mobility shift assays (EMSA)
Protein was prepared from whole cell or cytoplasmic extracts and Western
blots were performed according to standard protocols. Rabbit anti-human IKKβ
was purchased from Cell Signaling Technology (Boston, MA) and anti-actin-HRP
and anti-rabbit-HRP was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). To detect NF-κB activity, nuclear protein was extracted and EMSA was
performed. Briefly, cells were washed in PBS then suspended in CE buffer
(10mM HEPES (pH7.9), 10mM KCl, 0.1mM EDTA, 0.3% NP-40, and 1x Protease
inhibitors) for 5 min. at 4°C, then centrifuged for 5 min at 1600xg. The
supernatant (cytoplasmic extract) was removed and the remaining pellet was
washed in CE buffer without NP-40. Finally the pellet was suspended in NE
buffer (20mM HEPES (pH7.9), 0.4M NaCl, 1mM EDTA, 25% glycerol) and
incubated on ice for 10 minutes with intermittent vortexing. The supernatant
(nuclear extract) was collected after centrifugation (16,000xg for 5 min). To
detect NF-κB activity, the following hairpin oligonucleotide was used as a probe:
GAGAGGGGATTCCCCGATTACCTTTCGGGGAATCCCCTCT.

The

probe

was

annealed and end-labeled with Gamma-ATP using T4 polynucleotide kinase
according to the manufacturer’s instructions (New England Biolabs). Labeled
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probes (25,000cpm/rxn) were incubated with nuclear extracts, NF-κB Binding
Buffer (50mM Tris (pH7.6), 250mM NaCl, 2.5mM EDTA, 5mM DTT, 1mg/mL
BSA, 25% Glycerol) and 1ug poly-dI:dC for 20 min at room temperature and
separated on a 10% non-denaturing polyacrylamide gel with 0.25X TBE running
buffer. The gel was dried at 80ºC for 2 hours and then exposed to film overnight
at –80ºC.
2.3.8. RNase protection assay (RPA) and qPCR
RNA was purified using Trizol® Reagent (Invitrogen, Carlsbad, CA)
following the manufacturer’s instructions for RPA. To detect mRNA expression of
cytokines in DC, RPA probe sets hCK2b, mCK2b and mCK3b (BD Pharmingen,
San Diego, CA) were used. For qPCR, RNA was purified from culture using the
RNEasy kit from Qiagen (Valencia, CA) according to the manufacturer’s protocol
including the on-column DNase digestion. Lung tissue was homogenized in a
bead beater (BioSpec, Bartlesville, OK) prior to extraction by adding 60 mg of
lung tissue to 1.2 ml Buffer RLT + 2-ME (Qiagen RNEasy kit) and filling a 2.0 ml
tube with 1.0 mm glass beads. Samples were subjected to 3-4 50-second
homogenizations on the bead beater. RNA samples were reverse-transcribed
and then subjected to quantitative PCR analysis in an Applied Biosystems
7900HT Sequence Detection System (Carlsbad, CA) with SYBR Green I Master
Mix (Applied Biosystems, Carlsbad, CA) using gene-specific primers. Primer
quality was validated by checking for a single dissociation curve. All samples
were run in triplicate and were normalized to β-actin. Primers used for qPCR are
listed in Table 2.1.
23

Table 2.1. RT-PCR primer list. Primers were used for RT-PCR in mouse lung
cells and BMDC.
Gene
β-actin
IFNβ
IL-6
TNFα
IL-12p35
IL-12p40

Forward Primer

Reverse Primer

5’-ATGGAATCCTGTGGCATCCAT-3’

5’-CCACCAGACAACACTGTGTTGG-3’

5’-AGCTCCAAGAAGGACGAACAT-3’

5’-GCCCTGTAGGTGAGGTTGATCT-3’

5’-CTGCAAGAGACTTCCATCCAGTT-3’

5’AGGGAAGGCCGTGGTTGT-3’

5’-AGCCGATGGGTTGTACCTTGTCTA-3’

5’-TGAGATAGCAAATCGGCTGACGGT-3’

5’-ACCTGCTGAAGACCACAGATGACA-3’

5’-TAGCCAGGCAACTCTCGTTCTTGT-3’

5’-ATGTGGGAGCTGGAGAAAGACGTT-3’

5’-ATCTTCTTCAGGCGTGTCACAGGT-3’
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2.3.9. ELISA and ELISpot assays
Peripheral blood was collected from mice at D9 and/or D21 after
adenovirus administration via submandibular puncture and serum was collected.
Anti-GFP IgG ELISAs were performed as previously described (68). Relative
amounts of anti-GFP IgG were calculated by creating a linear regression model
using two-fold serial dilutions of GFP-positive serum. The relative difference of
each sample OD450 measurement was determined by best-fit curve. GFP
protein was purchased from Clontech Laboratories (Mountain View, CA). Antimouse IgG-HRP was purchased from Jackson ImmunoResearch Laboratories
(West Grove, PA). For detection of CD8 T cells secreting IFN-γ, enzyme-linked
immunosorbent spot (ELISpot) assays were performed as described (113).
Briefly, CD8 T cells were purified from whole splenocytes of mice by positive
selection using anti-CD8 coated magnetic beads (Miltenyi Biotec, Auburn, CA).
Whole draining lymph nodes from mice were mechanically disrupted and passed
through a 40 µm mesh filter to produce a single cell suspension. Mouse lungs
were processed as previously described (114) and the T cell enriched population
was used. Responder (CD8, lymph node or enriched lung) cells were incubated
at different concentrations per well, together with 1x105 stimulator cells (unpulsed
or peptide pulsed cells). EL4 cells were pulsed with the OVA peptide SIINFEKL
for OVA-specific ELISpots and P815 cells pulsed with the GFP peptide
HYLSTQSAL for GFP-specific ELISpots. Cells were cultured for 24 hours at 37ºC
and spots (IFN-γ producing cells) were developed. Purified anti-mouse IFN-γ
(capture) antibodies, biotinylated anti-mouse IFN-γ (detection) antibodies and
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streptavidin-HRP antibodies were purchased from eBioscience (San Diego, CA).
AEC detection substrate was purchased from BD Pharmingen (San Diego, CA).
Spot counting was done with an AID EliSpot Reader System (Autoimmun
Diagnostika GmbH, Strassberg, Germany).
2.3.10. Statistical analysis
All figures represent results from at least two independent experiments.
Where appropriate, results are expressed as mean +/- SEM.

2.4. Results
2.4.1. Constitutively-active IKKβ
β induces maturation of DCs and induction
of cytokines
IKKβ is the primary activator of NF-κB p50, RelA (p65) and cRel subunits
in response to most stimuli (17, 27, 41, 102). Mutation of serines 177 and 181 to
glutamic acid (IKKβEE) locks IKKβ into an active conformation and is sufficient
for activation of NF-κB (44, 46) We generated a replication-deficient adenovirus
type 5 that expresses IKKβEE (AdIKK) and GFP using dual CMV promoters (Fig
2.1A). HEK-293T cells infected with AdIKK showed high IKKβ expression and
nuclear NF-κB translocation compared to an adenovirus that only expresses
GFP (AdGFP) (Fig. 2.1B).
Dendritic cells are the main cellular link between innate and adaptive
immunity (22). As such, they can play an integral part in successful vaccineinduced immunity. They have the ability to react directly to TLR stimulation and
subsequently activate T cells and the adaptive immune system through direct
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Figure 2.1. Impact of AdIKK infection on murine and human dendritic cells. (A)
Depiction of the DUAL-GFP-CCM shuttle vector used to create AdGFP and AdIKK.
(B) Western blot showing IKKβ expression in HEK-293T cells uninfected (UI) or
infected with AdGFP or AdIKK (MOI=5 or 20, 48h) (left), EMSA showing nuclear
expression of NF-κB in HEK-293T cells uninfected, infected with AdGFP or AdIKK
(MOI=5, 48h), or treated with TNFα (20 ng/ml, 2h). (C) Western blot showing IKKβ
expression in murine BMDC uninfected or infected with AdGFP or AdIKK (MOI=200,
48h). (D) FACS analysis of maturation markers on murine BMDC after infection with
AdGFP or AdIKK (MOI=200, 48h). Uninfected: shaded, AdGFP: solid black line,
AdIKK: dotted line. (E) FACS analysis of human MoDC after infection with AdGFP or
AdIKK (MOI=500, 48h) or treatment with LPS (10 ng/ml, 16h). Uninfected: shaded,
AdGFP: solid black line, AdIKK: dotted line, LPS: dashed line. Results are
representative of at least two independent experiments. GFP: AdGFP. IKK: AdIKK.
TNF: TNFα
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interaction with cells and cytokine production. Infection of murine BM-derived
DCs (BMDCs; generated as described (24)) with AdIKK induced high IKKβ within
48 hours (Fig 2.1C). Maturation of BMDC was also induced by AdIKK infection
via increased expression of key T-cell stimulatory molecules CD80, CD86, MHC
class II (I-Ab) and ICAM-1 shown by FACS (performed as described (24)).
Importantly, both AdIKK and AdGFP led to similar levels of GFP expression
following BMDC infection (Fig 2.1D). Infection of human MoDC with AdIKK also
resulted in increased expression of CD83 and CD86 to levels similar to those
induced by LPS stimulation (Fig 2.1E).
In contrast, AdIKK did not increase the expression of MHC class I (H2-Kb)
over AdGFP infected cells (Fig 2.1D). However, AdIKK increased expression of
IFN-β, IL-6 IL-12p40, IL-12p35 (Fig 2.2A) TNF-α, IL-1α and IL-1β (Figure 2.2B),
and protein expression of IL-6 and IL-12 (Fig. 2.2C). Infection of human MoDC
with AdIKK also resulted in increased expression of IL-12p35 and p40, IL-1a, IL1b, IL-1RA, IL-6, and IFN-γ (Fig 2.2D). While numerous signaling pathways are
known to participate in regulating DC function, these findings indicate that
activation of IKKβ is sufficient for robust induction of expression of key cell
surface molecules and cytokines in both mouse and human DC.
2.4.2. AdIKK induces the expression of both pro-inflammatory and T-cell
stimulating cytokines through p50 and cRel
Previous work in our lab has shown that different NF-κB subunits are
responsible for the induction of inflammatory cytokines and T cell-activating
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Figure 2.2. Impact of AdIKK infection on cytokine expression in dendritic cells. (A)
RT-PCR of C57Bl/6 BMDC showing cytokine induction after infecting cells with
AdGFP or AdIKK (MOI=200, 48h) or leaving cells uninfected (UI). Results are
averaged from triplicate samples +/- SEM. (B) RPA of C57Bl/6 BMDC showing
cytokine induction after AdGFP or AdIKK infection (MOI=200, 48h). (C) RPA of
human MoDC showing cytokine induction after AdGFP or AdIKK infection
(MOI=500, 48h). L.E.= long exposure. (D) ELISAs showing cytokine expression in
C57Bl/6 BMDC after infection with AdGFP or AdIKK (MOI=200, 48h). Samples were
run in triplicate and results are reported as average +/- SEM. Results are
representative of at least two independent experiments. GFP: AdGFP. IKK: AdIKK.
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cytokines in DC (24). To determine which canonical NF-κB subunits were
activated by AdIKK, we examined nuclear translocation of RelA/p65, cRel and
p50 in murine BMDCs after infection with AdGFP or AdIKK. Translocation of all
three subunits was increased in AdIKK-infected BMDCs compared to AdGFPinfected BMDCs (Figure 2.3A). We next determined whether RelA, cRel, or p50
were required for AdIKK-induced cytokine production. To this end, we used
BMDCs deficient in RelA or p50+cRel as described (24). Interestingly, unlike
LPS stimulation (24), RelA was not required for the induction of IL-6 in DCs after
AdIKK infection (Fig 2.3B). However, loss of p50 and cRel greatly decreased the
induction of IL-6, IL-12p40 and IL-12p35 (Fig 2.3B, C). These results indicate that
AdIKK infection predominantly activates cytokine expression through p50 and
cRel.
2.4.3. AdIKK infected DCs are not superior stimulators of T-cell responses
We next examined the ability of AdIKK-infected BMDCs to activate CD8+ T
cells. BMDCs were pulsed with ovalbumin (OVA) SIINFEKL peptide as described
(111) followed by infection with AdIKK or AdGFP. Surprisingly, although AdIKK
increased maturation marker and inflammatory cytokine expression, BMDCs
infected with AdIKK were incapable of increasing proliferation of OVA-specific
OT-1 T cells compared to AdGFP-infected or uninfected BMDCs (Fig 2.4A). This
is consistent with previous results showing no difference in MHC I molecule
expression on BMDC. Since AdIKK infection of BMDCs increased MHC class II
expression compared to AdGFP (Fig 2.1D), we also examined their ability to
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Figure 2.3. Role of classical NF-κB subunits in AdIKK responses. (A) BMDCs were
either uninfected or infected with AdGFP or AdIKK (MOI=200, 48h). Western blot
using BMDC nuclear extracts to detect canonical NF-κB subunits. (B, C) C57Bl/6 WT
and (B) RelA KO BMDCs or (C) p50/cRel KO BMDCs were either uninfected or
infected with AdGFP or AdIKK (MOI=200, 48h) and mRNA of the indicated cytokines
was determined by RT-PCR, with the results normalized to β-actin expression levels.
Results are representative of at least two independent experiments. UI: uninfected.
GFP: AdGFP. IKK: AdIKK
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induce proliferation of OVA-specific OT-II CD4+ T cells. However, no significant
difference in the proliferation of OT-II CD4+ T cells in any group was noticed (Fig
2.4B). Therefore, AdIKK-infected BMDCs are incapable of enhancing T cell
activation over control BMDCs.
We next examined the in vivo ability of AdIKK or AdGFP-infected BMDCs
to activate and induce functional differentiation of CD8+ T cells as determined by
IFNγ production using ELISPOT (115). Previous studies have characterized the
response of CD8+ T cells to the H2-Kd-restricted GFP peptide HYLSTQSAL
(116). BMDCs were infected with AdGFP or AdIKK and injected intravenously in
mice. However, no increase in GFP-specific IFN-γ-producing CD8+ T cells was
seen in mice injected with AdIKK-infected BMDCs compared to mice injected
with AdGFP-infected BMDCs after 14 days (Fig 2.4C). These experiments were
repeated using 3- or 10-fold fewer BMDCs, which were injected subcutaneously.
The subcutaneous administration also resulted in similar CD8+ T cell activation at
7 or 15 days after injection (data not shown).
BMDC vaccine trials commonly use peptide pulsing to introduce antigens
to the BMDC alone or in concert with virus infection (66). To this end, we used
BMDC pulsed with exogenous peptide (SIINFEKL) prior to infection.
Subcutaneous administration of pulsed and infected BMDC also showed no
increase in OVA-specific IFN-γ-producing CD8+ T cells in mice injected with
AdIKK-infected BMDCs compared to those injected with AdGFP-infected BMDCs
(Fig 2.4D). Therefore, despite the substantial increase in expression of co-
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Figure 2.4. Impact of IKK expression in BMDC on T cells. (A) BMDCs from C57Bl/6
mice were either left untreated or pulsed with 1nM SIINFEKL overnight and then
either infected with AdGFP or AdIKK (MOI=200, 48h) or left uninfected. 3Hthymidine incorporation was used to measure proliferation in triplicate samples. (B)
BMDC from C57Bl/6 mice were pulsed with 50nM OVA peptide (323-339) overnight
and infected (MOI=250, 24h). 3H-thymidine incorporation was used to measure
proliferation in triplicate samples. (C) Balb/C BMDCs were infected with AdGFP or
AdIKK (MOI=500, 48h) then 1x106 cells were injected intravenously into 3 Balb/C
mice per group. After 14 days, CD8+ T cells were isolated from pooled spleens of 3
mice and IFN-γ production was determined by ELISPOT. (D) C57Bl/6 BMDCs were
pulsed with SIINFEKL overnight and infected with AdGFP or AdIKK (MOI=250, 6h)
then 5x105 cells were injected s.c. into C57Bl/6 mice. After 6.5d, T cells were
isolated from pooled splenocytes and IFN-γ production was determined by
ELISPOT. Results are reported from triplicate wells as mean +/- SEM. Results are
representative of at least 2 independent experiments.
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stimulatory molecules and T-cell stimulating cytokines, AdIKK-infected BMDCs
are not superior T cell stimulators.
2.4.4. AdIKK-induced inflammation impacts the kinetics but not the
magnitude of adaptive immune response
Inflammation is known to stimulate adaptive immunity through multiple
mechanisms, including APC activation, increased recruitment of leukocytes to
inflammatory sites and lymphoid tissues, and direct effects on lymphocyte
functions.

We next determined whether potentially robust induction of pro-

inflammatory cytokines by AdIKK could affect T and B cell responses. To this
end, we used a pulmonary infection model that has previously been shown to
induce potent inflammation (117). We first determined in situ NF-κB activation
using a transgenic mouse strain in which NF-κB sites drive luciferase reporter
gene expression (118). As shown in Fig 2.5A, AdIKK, but not AdGFP, induced
strong luciferase reporter gene expression 48 hours after lung infection. The
luciferase expression is most intense in the central portion of the lungs because
the virus is administered intratracheally; therefore, cells near the entrance to the
lungs are most likely to be infected by the virus. Inflammation was evident in the
lungs of AdIKK-infected mice as early as 48 hours after administration and its
effects were still present at least 21 days after administration. Lungs of mice 48
hours after AdIKK administration were markedly congested, edematous and
infiltrated with numerous mixed inflammatory cells that formed prominent perivascular and peri-bronchiolar cuffs, and persisted for at least 21 days (Fig 2.5B).
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Figure 2.5. Impact of AdIKK on the pulmonary inflammatory response. (A) PBS
or 1x109 IFU AdGFP or AdIKK was administered intratracheally to NF-κBluciferase mice. 48h after virus administration, mice were injected
intraperitoneally with D-luciferin. 10 minutes later, mice were euthanized by CO2
inhalation and lungs were removed for imaging on a Caliper IVIS 200. Imaging
was completed within 15 minutes after tissue harvesting. (B) PBS or 1x109 IFU
AdGFP or AdIKK was administered intratracheally to C57Bl/6 mice. Lungs were
removed after 48h and H&E staining was done on formalin-fixed paraffin
embedded sections. Original magnification: 100x (1, 2, 5-7), 40x (3, 4), 200x (810). T: terminal bronchioles. AD: alveolar ducts. Scale bars for each row are the
same. Arrows denote perivascular cuffing of inflammatory cells. (C) PBS or
1x109 IFU AdGFP or AdIKK was administered intratracheally to 3 Balb/C mice
per group followed by measurement of TNFα and IL-6 expression in total lung
homogenates by RT-PCR 2 days later. Each symbol represents RT-PCR results
from an individual mouse, the horizontal line represents the mean +/- SEM.
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Terminal bronchioles (TB) 21 days following AdIKK-administration had
undergone squamous metaplasia, and were lined by multiple layers of flattened
to elongated cells with oval nuclei and slightly basophilic cytoplasm (Figure
2.5B.7), and alveolar septa (Figure 2.5B.10) were markedly thickened,
hemorrhagic, infiltrated by inflammatory cells, and comprised of prominent
bulging type II pneuomocytes, while alveolar sacs were filled with numerous
pulmonary macrophages.

In contrast, 48 hours after AdGFP administration,

lungs were only mildly congested and edematous. This mild inflammation
persisted for 21 days, but no other changes were evident. In agreement with the
above results, RT-PCR of homogenized lungs showed a 4-fold increase in the
pro-inflammatory cytokines IL-6 and TNFα after 48 hours in AdIKK-infected, but
not AdGFP-infected mice (Fig 2.5C)
We proceeded to characterize the potential effect of NF-κB driven
inflammation on the adaptive immune response to GFP as described above.
While there was no substantial difference in the percentage of GFP-specific T
cells at day 9 as determined by IFN-γ ELISPOT (not shown) the total number of
GFP-specific T cells was substantially greater in draining LN of AdIKK-infected
versus AdGFP-infected mice (Fig. 2.6A). In addition, there was a substantial
increase in size and total cell numbers of draining LN of AdIKK infected mice on
day 9 after infection (Fig. 2.6B). Importantly, the relative anti-GFP IgG response
(determined as described (119)), on day 9 was over 3-fold higher in mice that
received AdIKK compared to mice that received AdGFP (Fig 2.6C). In contrast,
the total LN cell numbers, the number of GFP-specific T cells (not shown), and
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Figure 2.6. Effect of AdIKK administration on the adaptive immune response. (A) 10
days after intratracheal virus administration, mediastinal LNs were harvested from 34 mice in each of two separate experiments, pooled and total LN cells were counted.
Total antigen-specific T-cell numbers were determined by ELISPOT in triplicate. The
relative Ag specific CD8+ T-cell numbers are from duplicate experiments plotted as
fold-change compared to the AdGFP (mean and SEM). (B) PBS or 1x109 IFU
AdGFP or AdIKK was administered intratracheally to Balb/C mice. 9 days after
administration, mediastinal lymph nodes were excised and embedded in Tissue Tek
OCT. Hematoxylin and Eosin staining was performed on 5 um frozen sections and
slides were imaged on an Aperio ScanScope XT Automated Slide Scanner. All
images are captured at the same magnification. Scale bars represent 500 um. (C)
Serum was pooled from 3 mice infected intratracheally with AdGFP or AdIKK after 9
and 21 days. The anti-GFP IgG response was measured by ELISA. Samples were
read in triplicate, relative antibody levels were determined by interpolation of a
dilution curve run in parallel to the samples. Results from duplicate experiments are
plotted as fold-change compared to the AdGFP controls (mean and SEM). (D)
Performed as in (C) except mice were injected s.c. in four locations with a total of
5x108 IFU AdGFP or AdIKK. Serum was collected at days 9 and 21 and an anti-GFP
IgG ELISA was performed and analyzed as in (C). Results are representative of at
least two independent experiments.
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anti-GFP antibody was not different at day 21 between AdGFP and AdIKKinfected mice (Fig 2.6C). Therefore, AdIKK impacts the kinetics but not the
overall magnitude of an adaptive immune response.
The patho-physiology of lungs makes them uniquely prone to induction of
robust inflammation following encounter with noxious or infectious agents. We
next determined if vaccination with AdIKK through alternative routes could also
impact the kinetics of an antibody response. However, subcutaneous AdIKK
injection had no potentiating effect on anti-GFP IgG levels on day 9 or 21 (Fig.
2.6D) nor did it induce a visible inflammatory response. These results were also
evident with a 10- and 50-fold reduction in the total virus injected (data not
shown). Therefore, the impact on kinetics of the adaptive immune response
appears to be evident only under conditions of robust inflammation, as seen in
the lungs. In conclusion, our results indicate that IKKβ primarily functions through
induction of strong pro-inflammatory signals that specifically enhance the kinetics
of an immune response to a viral vector.

2.5. Discussion
Previous studies have shown that adenovirus-mediated intracellular
expression of NIK can strongly enhance the magnitude of an adaptive immune
response in an adenovirus vaccine setting (see below) (119). Importantly, we
report here that IKKβ primarily impacts the kinetics but not the magnitude of Tcell or antibody responses. The impact on kinetics is likely the result of IKKβ40

induced cytokines such as TNFα and/or TNF family members, which are known
to enhance lymphocyte trafficking to LNs (120). Increased presence of
lymphocytes may therefore increase the likelihood of early activation of antigenspecific lymphocytes. Our results suggest that IKKβ may be useful as an
intracellular adjuvant in airway vaccines to achieve a more rapid immune
response.
NIK activation of IKKα can also lead to IRF3/7 activation (121, 122).

The

increased magnitude of the immune response triggered by NIK (119) may
therefore be mediated through combined activation of NF-κB and IRF3/7 by
IKKβ/IKKα. However, in our hands, AdNIK did not increase expression of DC
maturation markers and cytokines as seen with AdIKK (Fig 2.7A, B). In addition,
AdNIK poorly induced nuclear translocation of canonical and non-canonical (p52
and RelB) NF-κB subunits compared to AdIKK (Fig 2.7C). In contrast, both
AdIKK and AdNIK robustly induced NF-κB subunit nuclear translocation of HEK293T cells (Fig 2.7D). It is presently unclear why AdNIK fails to activate NF-κB in
BMDCs. Nonetheless, our results suggest that the main mechanism proposed by
Andreakos, et al. (119) to explain AdNIK adjuvant function in mice (i.e., robust
activation of NF-κB in APC), is unlikely to fully explain its immunostimulatory
effects. Loss of NIK in mice results in structural defects of secondary lymphoid
structures as well as impaired CD40 signaling and class switching in B cells
(123-125). It is therefore possible that NIK-induced activation of adaptive
immunity is mediated by profound changes in lymphoid tissue organization
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Figure 2.7. In vitro comparison of AdIKK and AdNIK infection. (A) Expression of costimulatory and maturation markers on BMDC infected with AdGFP, AdIKK, or
AdNIK (MOI=200, 48h) as determined by FACS, Uninfected: shaded, AdGFPinfected: solid line, AdIKK-infected: dashed line, AdNIK-infected: dotted line. (B)
Induction of cytokines in infected BMDC (MOI=200, 48h) shown by RT-PCR, results
normalized to β-actin expression levels and reported as mean +/- SEM. (C, D)
Western blots of nuclear extracts showing activation of NF-κB subunits in (C) BMDC
(MOI 200) and (D) HEK-293T cells (MOI 20) after 48h infection. E. EMSA showing
NF-κB activation in HEK293 cells after 48h infection with indicated MOI. Arrow
denotes NF-κB complexes.
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Thus,

the

immunostimulatory effects of NIK and IKKβ may be mediated by distinct
mechanisms. Recent studies indicate that microbial agents and inflammatory
cytokines have distinct effects on DC function, with only the former promoting
adaptive immunity (126). Based on our results, we suggest that microbial agentinduced activation of multiple pathways strongly promotes adaptive immunity
while the exclusive activation of inflammatory cytokines/IKKβ has a more limited
effect.
Major efforts are underway to understand how successful vaccines work
and to define novel adjuvants that can enhance protective adaptive immunity.
While virtually all microbial adjuvants activate NF-κB and IRF pathways, their
specific functions in promoting adaptive immunity are not clear. Our results
indicate that IKKβ canonical NF-κB pathway-induced inflammation impacts the
kinetics but not the magnitude of the immune response to an adenovirusencoded antigen. These findings therefore help define the individual role of a key
pathway induced by vaccine adjuvants. A similar strategy can help determine
how other major pathways, e.g., IKKα and IRF, promote adaptive immunity and
whether their efficacy and underlying mechanisms are distinct from those
induced by IKKβ.
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Chapter 3. Crucial role of NF-κ
κB in T cell mediated immune surveillance in
murine lung cancer.

3.1. Abstract
NF-κB is constitutively activated in many tumor types and known to play a
crucial role in suppressing cell death and enhancing tumor angiogenesis and
metastasis. NF-κB also promotes tumor-associated inflammation characterized
by neutrophil and macrophage presence, both of which promote tumor growth
and invasion. Also present within the tumor microenvironment are T cells, the
presence of which can be associated with immune surveillance and improved
patient survival. We investigated whether in addition to known tumor promoting
functions, NF-κB activation also promotes T cell mediated immune surveillance.
In both primary tumors and a metastatic tumor model, we found that NF-κB
expression in tumors rendered immunogenic through expression of Kb-OVA led
to tumor rejection or growth suppression. Tumor growth in athymic nude mice
was not affected by IKK, indicating regression was T cell mediated. IKK did not
increase the overall number of T cells, nor did it make LLC-OVA cells better
targets for T cells; it did increase recruitment of T cells to the tumor. Microarray
results showed increases in T cell chemokines, including CCL2 and CCL5.
Knock-down of CCL2 by Lentiviral shRNA in LLC-OVA-IKK cells resulted in
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abrogation of tumor regression. These results suggest that NF-κB is capable of
promoting immune surveillance in a subset of tumors through increased
recruitment of T cells.

3.2. Introduction
A link between inflammation and cancer has been suspected since the
19th century; however, we are only beginning to understand it (89, 127). One of
the main regulators of inflammation is the Nuclear Factor-κB (NF-κB) family of
transcription factors (32, 48, 102). The NF-κB family consists of five members
that form homodimers or heterodimers to regulate a plethora of genes. Activation
of NF-κB is dependent on phosphorylation of the Inhibitors of κB (IκB) by IKKβ
(classical pathway) and IKKα (alternative pathway) (17, 41, 105, 106). These
two pathways are responsible for activating genes regulating varied processes,
from inflammation and immunity to apoptosis (32, 37, 48, 88, 102, 128). As such,
NF-κB has been shown to play a role in a number of the hallmarks of cancer
(74), including self-sufficiency in growth signals, evasion of apoptosis, sustained
angiogenesis, and invasion and metastasis (78, 79, 83-87). Indeed, aberrant NFκB expression is present in many cancers including lung cancer (78), melanoma
(79), multiple myeloma (80), breast cancer (81), colorectal cancer (82), and
lymphoma (83).
We now know that other cells present within the tumor microenvironment
play as profound a role as intrinsic tumor mutations. NF-κB expression within the
tumor

microenvironment

can

promote

tumor-associated

inflammation
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characterized by the presence of neutrophils and macrophages, both of which
promote tumor growth and invasion (77, 129). Contrary to the presence of
inflammatory cells, the presence of T cells in the tumor microenvironment is
associated with increased patient survival and immune surveillance (130, 131). In
this study, we expressed constitutively active IKKβ in lung tumors to induce the
canonical pathway and determine if NF-κB expression in tumors can promote
immune surveillance.

3.3. Methods
3.3.1. Mice
Six to 8-week-old C57BL/6 mice were purchased from the National
Cancer Institute (Frederick, MD). Six to 8-week-old athymic nude mice and CB6
mice were purchased from Harlan Laboratories (Indianapolis, IN). Rag 2-/- mice
were kindly provided by Dr. Xue-Zhong Yu (Moffitt Cancer Center). All colonies
were maintained under specific pathogen free conditions. All experiments were
performed following the guidelines of the Moffitt Cancer Center and the
University of South Florida Institutional Animal Care and Use Committee.
3.3.2. Cell culture
Lewis Lung Carcinoma and Turin-Bologna (TUBO) cell lines were cultured
in DMEM supplemented with 10% fetal bovine serum (FBS), antibiotics, and
2mM L-glutamine. Human cells lines (H157) were cultured in RPMI
supplemented with 10% fetal bovine serum (FBS), antibiotics, and 2mM Lglutamine.
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3.3.3. Retroviral and lentiviral transduction
Retroviruses were prepared by transfecting HEK 293T cells with Kb-OVA,
MiG or IKKβEE and packaging vectors as previously shown (24). Retrovirus
transduced cells were sorted based on GFP expressing using a FACS Vantage
sorter (BD Biosciences, San Jose, CA). Lentiviruses were prepared by
transfecting HEK 293T cells with scrambled control pLKO.1 or pLKO.1
expressing shRNA specific for CCL2 (Open Biosystems) along with packaging
vectors (24). Lentivirally transduced cells were selected for puromycin resistance.
3.3.4. Flow cytometric analysis
All transfected cell lines were tested for expression of inserted genes
using FACS. MiG and IKKβ transfected lines were analyzed for GFP expression
and viability. Kb OVA expressing cell lines were incubated with anti-CD16/CD32
to block Fc binding, and stained with Kb OVA-phycoerytherin for 15-20 minutes
on ice. Kb-OVA expression was analyzed as well as viability. All lines showed
greater than 95% GFP and/or Kb-OVA expression. Antibodies were purchased
from BD Biosciences-Pharmingen (San Diego, CA). Tetramer staining was
completed as described with the following changes: cells were incubated for 5
minutes at RT with Fc block and DAPI was added to cells prior to analysis for
viability gating (132). p66 tetramer was kindly provided by E. Celis (Moffitt
Cancer Center, Tampa, FL) and H2-Kb OVA tetramer was purchased from
Beckman Coulter (Brea, CA). Flow cytometric analysis was performed on an
LSR II cytometer (BD Biosciences, San Jose, CA). Aggregates and dead cells
were excluded from analysis (110). Data were acquired using CellQuest software
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(BD Biosciences, San Jose, CA) and analyzed using FlowJo software (Tree Star,
Ashland, OR).
3.3.5. Western blotting and electrophoretic mobility shift assays (EMSA)
Protein was prepared from whole cell or cytoplasmic and nuclear extracts
and Western blots were performed according to standard protocols. Rabbit antihuman IKKβ was purchased from Cell Signaling Technology (Boston, MA) and all
other antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). To detect NF-κB activity, EMSA was performed as described in chapter 2.
3.3.6. ELISA and ELISpot assays
Supernatant was collected from LLC-OVA-IKK cells after 48h of culture.
Anti-CCL2 ELISA was performed to confirm CCL2 knockdown using the Mouse
CCL2 ELISA Ready-SET-Go® kit from eBioscience (San Diego, CA) according
to the manufacturer’s instructions. Samples were run in triplicate.
ELISpot assays were performed as described in chapter two with the
following changes: T cells were isolated from splenocytes of OT-I transgenic
mice and LLC-OVA-MiG or LLC-OVA-IKK cells were used as targets.
3.3.7. Tumor studies
Cells were harvested in logarithmic growth after being cultured for less
than two weeks and washed once in injection medium (phenol-free DMEM
supplemented with 2% FBS) and counted. 5x105 LLC cells were injected either
subcutaneously (s.c.) (in a volume of 100 µl) in the right flank or intravenously
(i.v.) (in a volume of 200 µl) in the tail vein. 3x105 TUBO cells were injected s.c.
in a volume of 100 µl. Subcutaneous tumors were monitored for growth and
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measured 2-3 times per week. Mice receiving intravenous LLC injections were
monitored for morbidity. Mice were sacrificed when s.c. tumors reached a
diameter of 20 mm or when they showed signs of morbidity (i.v. or s.c.). Tumor
volume was calculated as previously described (133).

Mice receiving TUBO cells were split into treatment and non-treatment
groups on day 5, with a bias towards larger tumors in the treatment group.
Immunization with p66 TriVax was performed as described on day 5 (132). The
p66 peptide specific for TUBO cells was previously described (134).
3.3.8. RNA analysis
RNA was isolated using a Qiagen RNEasy kit, then reverse-transcribed
and subjected to quantitative PCR analysis in an Applied Biosystems 7900HT
Sequence Detection System (Carlsbad, CA) with SYBR Green I Master Mix
(Applied Biosystems, Carlsbad, CA) using gene-specific primers. Primer quality
was validated by checking for a single dissociation curve. All samples were run in
triplicate and were normalized to β-actin.
Microarray using Mouse Genome 430 2.0 Arrays was performed on
poly(A) RNA specifically converted to cDNA and then amplified and labeled with
biotin using the Ambion Message Amp Premier RNA Amplification Kit (Life
Technologies, Grand Island, NY) following the manufacturer’s protocol (135).
Hybridization with the biotin-labeled RNA, staining, and scanning of the chips
followed the prescribed procedure outlined in the Affymetrix technical manual
(136). Results were analyzed using Affymetrix GeneChip Operating Software
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(GCOS) using the MAS 5.0 algorithm. Genes were considered changed if there
was a 2-fold difference in signal compared to the control.
3.3.9. Histology
Mouse tumors were excised and sections were embedded in Tissue Tek
OCT compound (Sakura Fintek, Torrance, CA) or placed in 10% formalin and
subsequently embedded in paraffin blocks (FFPE). Frozen sections of mouse
tumors were stained with anti-CD8 and the Rat-IgG HRP detection kit from BD
Biosciences. Mouse lungs were insufflated in 10% formalin and paraffinembedded prior to H&E staining. Lung sections were imaged on an Aperio
ScanScope XT Automated Slide Scanner (Vista, CA).
3.3.10. Statistical analysis
Relative tumor growth analyzed with Fisher’s Exact T test. Tetramer
staining was analyzed using the Student’s T test with Welch’s correction.

3.4. Results
3.4.1. Critical role of IKKβ
β/NF-κ
κB in T cell-induced tumor rejection
Poorly immunogenic Lewis lung carcinoma (LLC) was rendered
immunogenic by expression of Kb-OVA (a single polypeptide encoding H-2Kb, β2microglobulin and ovalbumin SIINFEKL peptide) for recognition by CD8 T cells.
Expression of IKKβ in parental (Fig 3.1A) or LLC-OVA enhanced nuclear NF-κB,
comprising primarily of RelA/p65, and target gene CXCL1/KC expression (Fig
3.1B, C). However, both were substantially less than induced by TNFα (Fig 3.1B,
C). Instead, NF-κB activity in LLC-OVA-IKK was comparable to a human lung
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Figure 3.1. Impact of IKKβ expression on LLC cells. (A) EMSA showing nuclear
levels of NF-κB (top) and AP1 (bottom) in LLC-MiG, LLC-IKK, or LLC-MiG cells
treated with TNFα (B) EMSA showing NF-κB nuclear levels in LLC-OVA transduced
with control MiG, IKK and MiG treated with TNFα for 1h and 2h as indicated. (C)
RT-PCR showing KC/CXCL1 expression in LLC-OVA transduced with control MiG,
IKK and MiG treated with TNFα for 1h and 2h as indicated. Samples were run in
triplicate and reported as mean +/- SEM. (D) EMSA showing nuclear levels of NFκB in LLC-OVA-MiG, LLC-OVA-IKK, or H157 cell lines. TNFα treatment: 20 ng/ml.
Results are representative of at least two independent experiments.
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cancer cell line harboring KRAS and p53 mutations, which are known to activate
NF-κB (137) (Fig 3.1D). Compared to control LLC-MIG, LLC-IKK had no
significant effect on growth of non-immunogenic LLC in syngeneic C57BL/6 mice
(Fig 3.2A). In contrast, LLC-OVA-IKK tumors grew initially but were subsequently
rejected (Fig 3.2B). Combined results from 3 experiments indicated that once
tumors were perceptible, 10/11 LLC-OVA-MIG showed tumor growth while only
3/11 LLC-OVA-IKK showed similar growth (p=0.004, Fisher’s Exact Test) (Fig
3.2C). Importantly, a similar number of activated OVA-specific CD8 T cells were
detected in peripheral blood of mice receiving LLC-OVA-MIG and LLC-OVA-IKK
(Fig 3.2D) suggesting that reduced growth of LLC-OVA-IKK was not due to
impaired T cell priming. Using a metastatic LLC model, LLC-OVA-IKK showed
substantially fewer and smaller lung tumor foci than LLC-OVA-MIG (or LLC-MIG
and LLC-IKK) (Fig 3.2E, F). Finally, LLC-OVA-IKK grew robustly in Rag2-/- mice
(Fig 3.3A) and in athymic nude mice (Fig 3.3B), demonstrating a role of
lymphocytes, and more specifically, T cells, in immune rejection of LLC-OVAIKK.
We next determined the effect of NF-κB activation in vaccine induced
responses against the breast carcinoma TUBO line, which naturally express
Her2/neu/p66. Five days after tumor inoculation, when tumors were perceptible,
TUBO-MiG and TUBO-IKK injected mice were split into control (no vaccine) and
vaccine groups. Vaccinated mice received the previously characterized
Her2/Neu/p66 TriVax (132, 138) containing the p66 peptide, polyI:C as a TLR
agonist, and anti-CD40. TriVax-induced responses were determined in peripheral
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Figure 3.2. Impact of IKKβ expression on LLC growth and T cell response in
C57Bl/6 mice. (A)Tumor growth in C57Bl/6 mice inoculated s.c. with LLC-MiG and
LLC-IKK over indicated time periods. (B) Tumor growth in C57Bl/6 mice inoculated
s.c. LLC-OVA-MiG and LLC-OVA-IKK over indicated time periods. Each line
represents tumor growth in a single mouse. (C) C57Bl/6 mice received s.c.LLCOVA-MiG or LLC-OVA-IKK and tumor growth was monitored. Relative fold increase
in tumor volume at D21 post-inoculation compared to D4 post-inoculation.
Combined results from 3 independent experiments are shown. (D) H2Kb-OVA
tetramer analysis of peripheral blood on D10 from naïve mice or mice receiving
LLC-OVA-MiG or LLC-OVA-IKK cells s.c. (E) H&E staining of lungs from mice 24
days after receiving i.v. LLC-MiG or LLC-IKK (left) or LLC-OVA-MiG or LLC-OVAIKK. Scale bars: 4 mm (F) H&E staining of lungs from mice 24 days after receiving
i.v. immunogenic LLC-OVA-MiG or LLC-OVA-IKK. Scale bars: 1 mm (top), and 200
µm (bottom) Results are representative of lungs from 4 mice for each condition.
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A.
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Figure 3.3. Impact of lymphocytes on immunogenic LLC tumor growth. (A, B)
Tumor growth in (A) RAG2-/- mice or (B) athymic mice inoculated s.c. with LLCOVA-MiG or LLC-OVA-IKK. Results are representative of two independent
experiments. Each line represents tumor growth in a single mouse.
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blood (Fig 3.4A). The addition of IKK had no impact on activation of p66-specific
T cells. Tumor growth of vaccinated TUBO-MIG and TUBO-IKK was then
determined relative to their unvaccinated counterparts. While vaccination
reduced growth of both TUBO-MIG and TUBO-IKK tumors, the reduction was
significantly more pronounced in TUBO-IKK (p=0.025) (Fig 3.4B). These results
show that NF-κB activation enhances tumor rejection in spontaneous and
vaccine-induced T cell priming models.
3.4.2. NF-κ
κB induced T cell chemokine expression is crucial for tumor
rejection
We next investigated potential mechanism(s) of rejection of LLC-OVA-IKK.
As shown above, rejection was unlikely to be mediated by increased numbers of
OVA-specific CD8 T cells (Fig 3.2D) In addition, LLC-OVA-IKK were not superior
stimulators of CD8 T cell function as determined IFN-γ production (Fig 3.5A). We
next examined whether NF-κB activation increases CD8 T cell recruitment in
tumors. Immunohistochemistry to determine CD8 T cell presence within tumors
on day 9 (i.e., prior to regression) demonstrated the presence of a small number
of CD8 T cells in LLC-OVA-MIG tumors (Fig 3.5B). In striking contrast, IKK
tumors showed greatly increased CD8 T cell presence as well substantial areas
of tumor necrosis (Fig 3.5B). These results indicate that increased CD8 T cell
recruitment may be primary reason for rejection of IKK expressing tumors.
To identify potential T cell chemokines involved, we performed microarray
analysis of LLC-OVA-MIG and LLC-OVA-IKK cells. We used a 2-fold cutoff to
identify genes regulated by IKKβ/NF-κB (Table 3.1). Microarray analysis
identified 88 unique genes that were upregulated at least 2-fold in LLC-OVA-IKK
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A.

B.

Figure 3.4. Impact of IKKβ expression on TUBO response to p66 TriVax.
(A) Tetramer analysis of peripheral blood on day 10 from naïve mice or mice
receiving TUBO-MiG or TUBO-IKK with or without TriVax vaccination.
Vaccination given on day 5. Results are representative of at least two
independent experiments. P value: Student’s T test with Welch’s correction. (B)
CB6 mice received s.c. TUBO-MiG or TUBO-IKK. After 5 days, half of the mice
in each group received p66 TriVax and tumor growth was monitored. Tumor
growth of all mice was calculated at D21 relative to D5 and vaccinated mice
were compared relative to their unvaccinated counterparts. Results are
compiled from two separate experiments. P value: Fisher’s Exact Test. Results
are plotted as a separate mouse for each point with mean +/- SEM.
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Figure 3.5. Mechanism for T cell-induced tumor regression. ELISpot of OT-I T
cells cultured with LLC-parental, LLC-OVA, LLC-OVA-MiG, or LLC-OVA-IKK
tumor cells. 1x105 LLC targets/well. Samples were run in triplicate with results
reported as mean +/- SEM. (B) C57Bl/6 mice received s.c. LLC-OVA-MiG or
LLC-OVA-IKK. Tumors were excised at D9. Frozen sections were cut and
stained for CD8 using IHC. Scale bars: 50x= 150 mm and 200x= 50 mm.
Results are representative of at least two independent experiments.
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Table 3.1. Positive impact of IKKβ on genes expressed in LLC-OVA tumor cells.
Genes were identified as being increased over 2-fold in LLC-OVA-IKK cells
compared to LLC-OVA-MiG cells by mircroarray. Genes are listed in order of
decreasing fold-induction. Multiple probe sets for the same genes are listed and
a total of 88 unique genes are upregulated in LLC-OVA-IKK cells compared to
LLC-OVA-MiG cells.
Gene Symbol
C3
Mmp9
Casp4
Traf1
Mmp9
Tmem176a
LOC100416221
Gdpd5
Saa3
Pcdh1
Spt1
A4galt
Bcl3
Nfkbie
Fam84a
Bicd1
Cxcl10
Ccl5
4930528F23Rik
Tmem176a
Tmem176b
Tmem176a
Zfp711
Gfra2
Gbp2
Rbp2
H2-K1
Dclk1
A730089K16Rik
Stab1
Fabp4
Gpr176
Vgf
Tnfrsf9
1700049E17Rik2

Probeset
1423954_at
1448291_at
1449591_at
1423602_at
1416298_at
1425603_at
1441746_at
1424150_at
1450826_a_at
1452294_at
1448168_a_at
1455338_at
1418133_at
1458299_s_at
1425452_s_at
1437534_at
1418930_at
1418126_at
1431648_at
1423909_at
1418004_a_at
1441811_x_at
1432750_at
1433716_x_at
1418240_at
1422846_at
1427746_x_at
1424270_at
1437263_at
1450199_a_at
1417023_a_at
1442116_at
1436094_at
1460469_at
1430323_at

Experiment 1

Experiment 2

Fold Change

Fold Change

Average

184.83
95.62
85.50
15.39
56.08
14.97
31.33
5.39
23.19
26.00
28.67
22.82
4.11
20.27
19.89
12.77
11.93
18.09
11.42
12.19
6.94
9.88
2.43
10.93
18.08
10.15
3.21
17.32
9.50
12.79
6.79
13.98
6.44
9.76
2.71

90.55
18.34
17.08
60.79
19.51
28.48
8.32
33.77
9.45
6.55
2.94
7.45
26.11
9.16
8.35
14.38
14.05
7.72
13.89
12.23
17.37
14.23
21.60
11.62
3.54
11.18
18.03
2.78
10.33
5.73
11.05
2.37
7.79
4.08
10.58

137.69
56.98
51.29
38.09
37.80
21.72
19.83
19.58
16.32
16.28
15.80
15.13
15.11
14.71
14.12
13.57
12.99
12.90
12.65
12.21
12.15
12.06
12.01
11.27
10.81
10.66
10.62
10.05
9.92
9.26
8.92
8.17
7.11
6.92
6.65
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Table 3.1 (continued).
Gene Symbol
Rrad
Nfkbie
Ncf4
Cd82
Ubash3a
Slc39a4
Ccl2
Ass1
Dram1
Ccdc34
Tpbpa
Slc26a3
Ccl7
Dclk1
Ecscr
Cxcl1
Arhgef3
Mmp13
Fas
Rnd1
Cxcl1
Ikbke
Samsn1
Relb
Hcn1
Nfkbia
Vegfc
LOC100044874
Sdk1
Trim66
Gm9855
Vegfc
Col8a1
Nfkbia
Vegfc
Pls1
Dclk1
Upp1
Slc12a8
Cxcl5

Probeset
1422562_at
1431843_a_at
1418465_at
1416401_at
1431698_at
1451139_at
1420380_at
1416239_at
1424524_at
1453758_at
1415809_at
1427547_a_at
1421228_at
1424271_at
1437451_at
1457644_s_at
1424250_a_at
1417256_at
1460251_at
1455197_at
1419209_at
1417813_at
1421457_a_at
1417856_at
1450193_at
1448306_at
1419417_at
1424948_x_at
1440566_at
1456967_at
1454180_at
1439766_x_at
1418441_at
1449731_s_at
1440739_at
1460406_at
1451289_at
1448562_at
1420334_at
1419728_at

Experiment 1

Experiment 2

Fold Change

Fold Change

10.91
7.86
4.44
4.36
3.49
5.69
5.33
5.90
2.79
7.29
5.67
2.79
5.66
6.79
5.26
7.08
4.06
5.05
6.49
6.00
4.87
4.42
5.05
4.46
3.86
4.77
3.48
2.79
2.57
3.35
2.86
3.42
4.50
3.55
3.62
4.26
4.14
3.94
3.50
3.56

2.04
5.00
8.31
7.82
8.30
5.45
5.50
4.86
7.96
2.88
4.44
6.90
4.03
2.83
4.15
2.33
5.18
4.07
2.57
2.49
3.58
3.77
3.06
3.54
3.70
2.77
3.77
4.31
4.47
3.34
3.80
3.14
2.04
2.82
2.73
2.01
2.13
2.13
2.56
2.30

Average
6.48
6.43
6.37
6.09
5.89
5.57
5.42
5.38
5.37
5.08
5.05
4.85
4.84
4.81
4.71
4.71
4.62
4.56
4.53
4.25
4.22
4.10
4.06
4.00
3.78
3.77
3.63
3.55
3.52
3.35
3.33
3.28
3.27
3.19
3.18
3.13
3.13
3.03
3.03
2.93
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Table 3.1 (continued).
Gene Symbol
Col8a1
Ptpn22
Serpine2
Gfra2
Nlrp3
Col8a1
Cd34
Gbp2
Arhgdib
Slc43a2
Igfbp7
Ubxn10
Marcks
Ttc39c
Nfkbia
Casp1
Clec4e
Scin
Rims1
Zfpm2
C1s Gm5077
Mmp3
H2-K1
Casp12
Limd2
Fjx1
Cxcl1
Nfasc
Med8
Nfkbia
Pdgfra

Probeset
1418440_at
1417995_at
1416666_at
1459847_x_at
1425412_at
1455627_at
1416072_at
1435906_x_at
1426454_at
1434308_at
1423584_at
1426007_a_at
1415971_at
1426223_at
1438157_s_at
1449265_at
1420330_at
1450276_a_at
1438305_at
1444803_at
1424041_s_at
1418945_at
1425336_x_at
1449297_at
1447766_x_at
1422733_at
1441855_x_at
1459113_at
1442417_at
1420088_at
1421917_at

Experiment 1

Experiment 2

Fold Change

Fold Change

3.00
3.13
2.35
3.42
2.43
2.55
2.65
2.32
2.84
2.63
2.46
2.19
2.38
2.77
2.73
2.35
2.56
2.60
2.07
2.38
2.48
2.55
2.62
2.09
2.01
2.57
2.11
2.33
2.06
2.19
2.19

2.84
2.69
3.24
2.10
3.02
2.83
2.73
3.01
2.44
2.46
2.63
2.88
2.68
2.28
2.30
2.53
2.26
2.22
2.71
2.38
2.26
2.18
2.10
2.56
2.64
2.06
2.52
2.21
2.40
2.09
2.07

Average
2.92
2.91
2.80
2.76
2.73
2.69
2.69
2.66
2.64
2.55
2.54
2.53
2.53
2.52
2.52
2.44
2.41
2.41
2.39
2.38
2.37
2.37
2.36
2.33
2.32
2.32
2.32
2.27
2.23
2.14
2.13
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cells compared to LLC-OVA-MiG cells. These included multiple chemokines
involved in both T cell and neutrophil chemotaxis (Fig 3.6A, Table 3.2). Amongst
T cell chemokines identified, CCL2, CCL5 and CXCL10 are known to mediate
activated T cell chemotaxis (139). RT-PCR confirmed upregulation of CCL2,
CCL5 (Fig 3.6B) and other chemokines (data not shown) in LLC-OVA-IKK. CCL2
in particular exhibited high net expression in LLC-OVA-IKK (Fig 3.6A). Previous
studies have indicated conflicting roles for CCL2 in anti-tumor T cell responses
and an important role in breast cancer metastasis (140-142). Given these diverse
functions, we determined whether CCL2 was specifically required for rejection of
LLC-OVA-IKK by knockdown (KD) of CCL2 expression with shRNA-expressing
lentiviruses. We identified an shRNA that led to greater than 80% reduction in
CCL2 protein expression by ELISA (Fig 3.6C). CCL2 KD did not impact LLC
growth in vitro (data not shown). LLC-OVA-IKK transduced with control or CCL2
lentivirus resulted in similar expansion of OVA-specific T cells (Fig 3.6 D).
However, while control LLC-OVA-IKK tumors were readily rejected, CCL2 KD
resulted in robust tumor growth (Fig 3.6E). These results therefore identify CCL2
as a crucial NF-κB target gene that is required for LLC rejection.

3.5. Discussion
The tumor promoting functions of NF-κB have been extensively
documented. We report here that in immunogenic tumors or following
administration of anti-tumor vaccines, high NF-κB activity leads to tumor rejection
and/or retardation of tumor growth.
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A.

C.

B.

D.

E.

Figure 3.6. Impact of T cell chemokines on tumor rejection. (A)Transcript signal
(left) and fold increase (right) of chemokines induced by LLC-OVA-IKK at least
two-fold over LLC-OVA-MiG determined by microarray. Genes reported as
mean +/- SEM. (B) Tetramer analysis of peripheral blood on D14 from naïve
mice or mice receiving LLC-OVA-IKK, LLC-OVA-IKK-Lenti control or LLC-OVAIKK-CCL2. Each point represents data from a single mouse. (C) RT-PCR
showing CCL2 and CCL5 expression in LLC parental, LLC transduced with
OVA and LLC transduced with OVA+MiG or OVA+IKK. Results normalized to βactin levels. Samples were run in triplicate and reported as average +/- SEM.
(E) LLC-OVA-IKK-Lenti control and LLC-OVA-IKK-CCL2 cells were injected s.c.
in C57Bl/6 mice and tumor growth was monitored. Each line represents growth
in a single mouse. All results are representative of at least two independent
experiments.
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Table 3.2. Positive impact of IKKβ on chemokines expressed in LLC-OVA tumor
cells. Chemokines were identified as being increased over 2-fold in LLC-OVAIKK cells compared to LLC-OVA-MiG cells by mircroarray. Genes are listed in
order of decreasing fold-induction.
Gene Symbol

Probeset

Experiment 1 Experiment 2
Fold Induction Fold Induction

Average
Fold Induction

Cxcl10

1418930_at

11.93

14.05

12.99

Ccl5

1418126_at

18.09

7.72

12.90

Ccl2

1420380_at

5.33

5.50

5.42

Ccl7

1421228_at

5.66

4.03

4.84

Cxcl1

1457644_s_at

7.08

2.33

4.71

Cxcl1

1419209_at

4.87

3.58

4.22

Cxcl5

1419728_at

3.56

2.30

2.93

Cxcl1

1441855_x_at

2.11

2.52

2.32
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Using tumors rendered immunogenic by antigen expression or following
administration of anti-tumor vaccines, we found that high NF-κB activity leads to
tumor rejection and/or growth suppression. Studies in RAG2-/- mice, which lack
an adaptive immune system (143) and athymic nude mice that lack T cells (144)
suggested regression was mediated in a T cell-dependent manner. Growth of
LLC-OVA-MiG tumors was substantially reduced in athymic nude mice compared
to RAG2-/- mice. This is most likely due to enhanced cytotoxic activity of natural
killer (NK) cells present in the athymic nude mice (145).
We determined that the immunogenic tumors expressing IKK were
capable of increased recruitment of T cells through increased expression of T cell
chemokines, such as CCL2 and CCL5. Whether the T cells present in the tumors
are specific for the expressed antigen, Kb-OVA, remains to be determined;
however, that is likely the case because IKK expression in non-immunogenic
LLC tumors had no effect on growth.
As mentioned above, T cell-mediated tumor regression was the result of
increased chemokine expression in LLC-OVA-IKK cells. Microarray analysis of
the tumor lines showed that the T cell chemokine CCL2 had the highest overall
expression (although not the highest fold-induction). Knock-down of CCL2 in
LLC-OVA-IKK abrogated tumor regression. Current research indicates conflicting
roles for CCL2 in cancer (90, 140-142). The role of CCL2 may vary depending on
its temporal and spatial expression pattern. Our model expressed CCL2 from the
point of tumor ‘initiation’, and although tumors grew initially, early growth may
have resulted from lower CCL2 levels. As the tumors got progressively larger,
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more CCL2 was produced and the chemokine gradient increased allowing better
recruitment of T cells.
CCL2 was not the only T cell chemokine induced by IKK expression, nor
did it have the highest fold-induction. Other chemokines identified by our
microarray data may also be playing a role in T cell-mediated tumor regression.
While our results indicate a crucial role for NF-κB regulated T cell chemokines in
tumor rejection, multiple additional NF-κB controlled pathways (e.g. antigen
processing and presentation, expression of T cell stimulatory cytokines) may also
play an important role.
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Chapter 4. Concluding remarks and implications of IKKβ
β-induced NF-κ
κB
activation
The transcription factor NF-κB is one of the main regulators of
inflammation and the immune response. NF-κB is ubiquitously expressed and is
capable of activating numerous varied genes, from those involved in inhibition of
apoptosis to activation of the immune response. Underscoring its central role in
immunity, it is also involved in numerous diseases, from infections to
autoimmunity and cancer (31, 37, 48, 102). Activation of NF-κB through the
classical pathway requires functional IKKβ (42). Using constitutively active IKKβ,
the studies presented here highlight two host-beneficial roles of activation of the
classical NF-κB pathway.

4.1. IKKβ
β-induced inflammation impacts the kinetics but not the magnitude
of the immune response to a viral vector
In the second chapter, we examined the role of IKKβ-induced NF-κB
activation of an immune response to a viral vaccine vector. We found that IKKβ
was capable of enhancing the kinetics of the immune response, but not the
magnitude of the response. This impact is most likely through the induction of
inflammatory cytokines, such as TNFα induced by IKKβ that are capable of
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increasing lymphocyte trafficking to lymph nodes (120). Importantly, these results
were only evident in cases of robust inflammation, as subcutaneous
administration of AdIKK, which did not induce noticeable inflammation, was
incapable of enhancing the kinetics of the immune response.
Surprisingly, while AdIKK induced increased expression of inflammatory
cytokines and maturation markers in BMDCs, these increases were unable to
enhance activation of T cells by the BMDCs over AdGFP infected BMDCs.
Infection of BMDCs with adenovirus alone makes them capable of inducing a T
cell response both in vitro and in vivo in an NF-κB-dependent manner (72).
Because adenovirus already activates T cells in an NF-κB dependent manner,
any further activation of DC through NF-κB may have minimal effect on T cell
activation.
One additional caveat of our in vivo BMDC results is that the SIINFEKL
OVA peptide is a very strong activator of T cells. Uninfected BMDC pulsed with
SIINFEKL activated CD8 T cells to a similar level as our SIINFEKL-pulsed and
AdIKK infected BMDC (Fig 2.3D). It would be interesting to examine the impact
of AdIKK infection of BMDC in a less immunogenic setting, such as that of an
anti-tumor immune response. Current dendritic cell based vaccines for tumor
immunotherapy have fallen short of the goal of tumor eradication. This is due, at
least in part, to the tolerogenic tumor microenvironment (66). In this setting,
AdIKK infection of dendritic cells may be able to improve the anti-tumor immune
response by overcoming tolerance. To examine this possibility, one could inject
mice with tumor cells expressing known tumor associated antigens (TAA). These
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mice could then be treated with DCs pulsed with the TAAs and infected with
AdIKK.
In a similar study, AdNIK was shown to strongly enhance the magnitude of
an adaptive immune response in an adenovirus vaccine setting (119). Here,
AdNIK enhanced the type I T helper response through increased IgG2a
production, T cell proliferation, IFN-γ production and cytotoxic T cells. NIK is also
capable of activate IKKα and subsequent IRF family members (121, 122). This
cooperative activation of NF-κB and IRF may explain the positive findings of
Andreakos, et al.
In our hands, compared to AdIKK, AdNIK was unable to increase
maturation markers in BMDCs, nor could it increase nuclear translocation of NFκB family members. We did not examine the differences between the two viruses
further since our AdNIK showed no difference in our preliminary studies
compared to the control virus. Importantly, AdNIK was capable of increasing the
expression of NF-κB target genes (IL-6, IL-12p35, and IL-12p40) in DCs at least
two-fold compared to control. These results confirm that our AdNIK is functional,
just not to the extent seen by Andreakos, et al. Interestingly, the predominant NFκB subunit found in nuclear extracts from murine DCs infected with AdNIK was
RelB, with some increase in p50. RelA, cRel, and p52 levels were similar to
levels from AdGFP infected DCs. Infection of human HEK-293T cells with AdNIK
resulted in nuclear levels of RelA and cRel similar to AdIKK-induced levels. The
reasons for the differences between the two studies remain unclear; however,
the majority of their in vitro work was completed with human DC, whereas our
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comparison studies were done with murine DCs. The results from our western
blots suggest that AdNIK is a more potent activator of NF-κB in human cells (our
construct as well as that of Andreakos, et al uses human NIK). An additional
difference between the two studies is that we used 2.5x less adenovirus to infect
murine DCs, thus, any activation they saw in murine DC may be due to the
higher viral titer.
Major efforts are underway to understand how successful vaccines work
and to define novel adjuvants that can enhance protective adaptive immunity.
While virtually all microbial adjuvants activate NF-κB and IRF pathways (4, 63),
their specific functions in promoting adaptive immunity are not clear. Our results
indicate that inflammation induced by IKKβ activation of the canonical NF-κB
pathway impacts the kinetics but not the magnitude of the immune response to
an adenovirus-encoded antigen. These findings suggest that AdIKK may be
useful as an adjuvant to induce a more rapid immune response in a pulmonary
disease setting. Importantly, these results help define the individual role of a key
pathway induced by vaccine adjuvants.
The techniques developed in chapter 2 are now a powerful tool that can
help us 1) identify the roles of other transcription factors (IKKα, NIK, IRF3)
involved in the induction of adaptive immunity to adenovirus, either individually or
combined, and 2) determine if activation of these pathways can act impact on our
understanding of adenoviral immunity as well as the development of adenoviral
vaccine vectors.
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4.2. Crucial role of NF-κ
κB in T cell mediated immune surveillance in murine
lung cancer
In chapter 3, we examined the role of IKKβ-induced NF-κB in T cell
mediated tumor immune responses. The role of NF-κB in tumor promotion is well
documented in numerous cancer types (78, 79, 83-87). Despite the
overwhelming evidence that NF-κB activation promotes cancer, we show here
that IKKβ-induced activation of NF-κB can promote immune surveillance in at
least a subset of tumors.
Using tumors rendered immunogenic by antigen expression or following
administration of anti-tumor vaccines, we found that high NF-κB activity leads to
tumor rejection and/or growth suppression. Studies in RAG2-/- mice, which lack
an adaptive immune system (146) and athymic nude mice that lack T cells (144)
suggested regression was mediated in a T cell-dependent manner. We
determined that the immunogenic tumors expressing IKK were capable of
increased recruitment of T cells through increased expression of T cell
chemokines, such as CCL2 and CCL5. Whether the T cells present in the tumors
are specific for the expressed antigen, Kb-OVA, remains to be determined;
however, that is likely the case because IKK expression in non-immunogenic
LLC tumors had no effect on growth. This question can easily be answered by
using H2Kb-OVA tetramer to stain for T cells in tumors prior to regression.
As mentioned above, T cell-mediated tumor regression was the result of
increased chemokine expression in LLC-OVA-IKK cells. Microarray analysis of
the tumor lines showed that the T cell chemokine CCL2 had the highest overall
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expression (although not the highest fold-induction). Knock-down of CCL2 in
LLC-OVA-IKK abrogated tumor regression. Current research indicates conflicting
roles for CCL2 in cancer (90, 140-142). The role of CCL2 may vary depending on
its temporal and spatial expression pattern. Our model expressed CCL2 from the
point of tumor ‘initiation’, and although tumors grew initially, early growth may
have resulted from lower CCL2 levels. As the tumors got progressively larger,
more CCL2 was produced and the chemokine gradient increased allowing better
recruitment of T cells.
CCL2 was not the only T cell chemokine induced by IKK expression, nor
did it have the highest fold-induction. The other chemokines identified by our
microarray data may also be playing a role in T cell-mediated tumor regression.
CCL2 may not be the only chemokine involved; however, loss of CCL2 is enough
to abrogate tumor regression in mice. To determine if CCL2 is sufficient for tumor
regression, CCL2 must be over-expressed in LLC-OVA cells. If tumors
expressing CCL2 regress, it will demonstrate that CCL2 is sufficient for recruiting
CD8 T cells and mediating tumor regression. If tumors do not regress, it will
indicate that CCL2 induction by IKK is necessary but not sufficient for tumor
regression.
The mechanisms that determine whether NF-κB functions to promote
tumorigenesis or to promote anti-tumor immune responses remain to be
determined. The roles of individual members of the NF-κB family, as well as the
two pathways of activation need to be examined more closely. Knock-down of
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individual subunits may provide a clue as to what is driving these opposing
functions of NF-κB.
Clinically, NF-κB is thought of as something that should be inhibited in the
treatment of cancers. Here, we have shown that activation of NF-κB can promote
anti-tumor immune responses. Using constitutively active IKK is not a feasible
option for the treatment of cancers due to its known role in mediating
tumorigenesis and the substantial technical difficulties involved (147, 148).
However, identifying tumors displaying elevated NF-κB immune surveillance
functions may allow us to target them for immunotherapy. Based on our findings,
we would expect greater response to immunotherapy in NF-κB high versus NFκB low tumors.
Although NF-κB is typically associated with tumor promotion, we show
here that expression of NF-κB in lung tumors can enhance the anti-tumor
immune response. In mice, this surveillance is mediated by elevated chemokine
expression resulting in increased T cell recruitment to the tumor.

4.3. Concluding remarks
NF-κB is involved in the activation of many genes regulating the immune
response. Focusing on activation of the classical pathway of NF-κB through
IKKβ, we present two stories that highlight the ability of NF-κB to enhance the
immune response. In chapter 2, we show that increased activation of NF-κB in
an adenoviral vaccine setting can improve the kinetics of the immune response.
72

In the third chapter, we show evidence supporting NF-κB activation as a
mediator of increased tumor immune surveillance. These two studies provide
new insights into NF-κB activation of the immune response that can be
harnessed for improved treatment of diseases, including cancer.
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